Abstract Number: 2420 • 2015 ACR/ARHP Annual Meeting
Azathioprine for Glucocorticoid Resistant Non-Renal Henoch-Schönlein Purpura
Background/Purpose: Henoch-Schönlein purpura is the most common small vessel vasculitis in childhood and has a classic presentation of palpable purpura. The disease is typically benign…Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting
Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…Abstract Number: 2422 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a debilitating form of arthritis associated with systemic symptoms such as anemia, rash, leukocytosis, elevated erythrocyte sedimentation rate…Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…Abstract Number: 2424 • 2015 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program
Background/Purpose: Macrophage activation syndrome (MAS), a potentially fatal complication of systemic juvenile idiopathic arthritis (SJIA), was reported as an adverse event in both canakinumab and…Abstract Number: 2425 • 2015 ACR/ARHP Annual Meeting
Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)
Background/Purpose: Tocilizumab was recently approved for the treatment of systemic JIA (sJIA) and polyarticular JIA (pJIA). Published data on the tolerability of tocilizumab in patients…Abstract Number: 2426 • 2015 ACR/ARHP Annual Meeting
Medication Taper and Risk of Relapse in Pediatric Uveitis
Background/Purpose: Pediatric uveitis can be vision-threatening. Treatment typically consists of ocular steroids, methotrexate, and anti-tumor necrosis factor (TNF) agents. Optimal duration of treatment and risk…Abstract Number: 2427 • 2015 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Mycophenolate Mofetil in Childhood Primary Central Nervous System Vasculitis
Background/Purpose: Childhood primary central nervous system vasculitis (cPANCS) is an inflammatory brain disease targeting either small (angiography-negative) or medium-large (angiography-positive) central nervous system vessels. Vascular…Abstract Number: 2428 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis
Background/Purpose: The diagnosis of polyarticular JIA (pJIA) is made in childhood but the disease and the diagnosis are carried into adulthood. Adults with pJIA have…Abstract Number: 2429 • 2015 ACR/ARHP Annual Meeting
Varicella Vaccination in Patients with Pediatric Rheumatic Diseases Receiving Immunosuppression: Proposal of a Pre-Vaccination Checklist to Ensure Safety
Background/Purpose: Varicella zoster virus (VZV) infection is a serious preventable infection in patients (pts) receiving immunosuppression (IS). The purpose of this study was to determine…Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting
Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study
Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…Abstract Number: 2431 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Background/Purpose: The long-term safety of anti-tumor necrosis factor (TNF) drugs is particularly important in pediatric patients (pts) who may require prolonged treatment of their inflammatory…Abstract Number: 2432 • 2015 ACR/ARHP Annual Meeting
The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The main predictors of uveitis…Abstract Number: 2433 • 2015 ACR/ARHP Annual Meeting
Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Background/Purpose: Animal and humans data suggest that IFNγ plays a pathogenic role in HLH. A pilot trial in primary HLH with NI-0501, an anti-IFNγ monoclonal…Abstract Number: 2434 • 2015 ACR/ARHP Annual Meeting
Promis Tools for Measurement of Patient-Reported Outcomes in Children with Juvenile Arthritis
Background/Purpose: Child/parent perspectives on their own/their child's health are highly pertinent to disease management. PROMIS is a collection of patient-reported outcome measures that were developed…
ACR Meeting Abstracts